Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Negative/Low Hormone Receptor And/or HER2 POsitive Lobular Invasive Breast Carcinoma - A Real-World International Cohort Study (NAPOLI)

30 de agosto de 2026 actualizado por: Ferrucci Massimo, Istituto Oncologico Veneto IRCCS

NAPOLI: Negative/Low Hormone Receptor And/or HER2 POsitive Lobular Invasive Breast Carcinoma - A Real-World International Cohort Study

The NAPOLI Study is a retrospective multicenter observational study designed to characterize hormone receptor-negative/low invasive lobular carcinoma of the breast. The study will collect real-world clinicopathological, molecular, therapeutic and outcome data from patients diagnosed and treated at participating centers. The aim is to describe the clinical behavior, pathological features, receptor profile, treatments received and oncologic outcomes of this rare breast cancer subtype.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

Invasive lobular carcinoma (ILC) is the second most common histologic subtype of breast cancer (BC), accounting for approximately 10-15% of all invasive BCs. ILC is characterized by loss or dysfunction of the E-cadherin/catenin adhesion complex, typically due to CDH1 alterations, and by a distinctive discohesive and infiltrative growth pattern. These features translate into specific and unique biological, clinical and therapeutic challenges compared with invasive carcinoma of no-special type (IC-NST).

The majority of ILCs - up to 90% - are estrogen receptor (ER)-positive, progesterone receptor (PR)-positive and HER2-negative. In contrast, hormone receptor (HR)-negative ILC (ER and PR expression <1%), HR-low ILC (1-10% HR-positive cells), and HER2-positive (any HR expression) ILC are rare, biologically and clinically heterogeneous, and markedly underrepresented in clinical trials and large translational datasets. Moreover, the absence or very low expression of hormone receptors limits the role of endocrine therapy, thereby narrowing therapeutic options and potentially affecting prognosis. The efficacy of anti-HER2 therapies in ILC remains less defined than in IC-NST, due to the rarity of HER2 overexpression in breast cancer of lobular histotype (<10% of all ILC). Consequently, clinical outcomes and response to neoadjuvant therapies across both HR-positive/HER2-positive and HR-negative/HER2-positive represent an area where clinical data are lacking.

Recent genomic and transcriptomic studies have identified alterations involving pathways such as CDH1, ERBB2, TP53, PI3K/AKT/PTEN, and DNA damage response pathways, along with other potentially actionable molecular mechanisms. These findings suggest that HR-negative/low ILC may constitute a biologically distinct entity rather than simply an uncommon variant of conventional HR-positive lobular carcinoma, raising important questions regarding prognosis, optimal treatment sequencing, indications and response to neoadjuvant therapies, and the potential role of targeted and biomarker-driven treatments.

Triple-negative ILC (TN-ILC) is exceedingly rare, accounting for approximately 1-2% of all ILC and well below 1% of all invasive BCs, which largely explains their marked underrepresentation in prospective trials, and the consequent lack of disease-specific evidence to guide clinical management. Available evidence suggests that TN-ILC is not simply the lobular counterpart of conventional basal-like triple-negative BC. Indeed, when profiled by PAM50, the majority of TN-ILC are non-basal-like, in contrast to conventional TN IC-NST. Moreover, TN-ILC appears enriched for older age at diagnosis, pleomorphic and apocrine/histiocytoid morphology, androgen receptor (AR) expression, and luminal androgen receptor (LAR)-like biology. Importantly, TN-ILC has been reported to show poor responsiveness to conventional neoadjuvant chemotherapy despite aggressive clinical behavior, raising questions about the optimal systemic treatment strategy and the potential value of biomarker-driven approaches. The few dedicated series available consistently report an unfavorable course, with a pooled pathologic complete response (PCR) rate of approximately 22.5%: in the largest early-stage cohort described to date, 5- and 10-year invasive disease-free survival were only approximately 50% and 37%, respectively. In addition, potentially actionable ERBB2 mutations have been reported in up to ~20% of TN-ILC and, together with frequent enrichment in DNA-damage-response, recurrent ESRRA mutations and PI3K/AKT/PTEN pathway alterations, may represent tractable therapeutic vulnerabilities, including HER2 tyrosine-kinase inhibitors, PARP or PI3K/AKT inhibitors.

HER2-positive ILC represents another uncommon and clinically relevant subgroup. HER2 overexpression/amplification in ILC is more frequently observed in pleomorphic and high-grade variants, and may be associated with distinct clinicopathologic features, higher proliferative activity and worse prognosis than classic HR-positive/HER2-negative ILC. However, data specific to HER2-positive ILC remain sparse, and most recommendations are extrapolated from IC-NST cohorts. Whether patterns of response to anti-HER2 neoadjuvant therapy, rates of PCR, surgical outcomes and recurrence patterns differ from those observed in IC-NST remains insufficiently defined.

Apocrine differentiation in the lobular setting is of particular interest, as it represents a rare and potentially distinct phenotype, commonly associated with HR negativity, AR expression, HER2 pathway activation in a subset of cases, luminal androgen receptor (LAR) biology, and unique genomic alterations, thereby providing a biological rationale for AR-directed or other targeted therapeutic strategies. In the lobular setting, apocrine, pleomorphic and histiocytoid features may overlap morphologically and biologically. However, the true prevalence, genomic correlates, treatment patterns and outcomes of apocrine lobular tumors remain poorly characterized. In the ductal setting TN apocrine carcinomas have shown markedly low PCR rates to neoadjuvant chemotherapy (as low as ~7%, versus ~30% in non-apocrine TN BC), and LAR-subtype tumors achieve the lowest PCR across TN subtypes (~14% versus ~43%). As apocrine and LAR features are enriched in HR-negative/low ILC, comparably low chemosensitivity is expected in this setting, further supporting a dedicated, biomarker-driven therapeutic approach.

Because of the rarity of these subtypes, prospective randomized studies are unlikely to be carried out in the near future. A large international real-world cohort is therefore needed to clarify whether HR-negative/low ILC, apocrine/LAR-enriched lobular tumors and HER2-positive ILC represent clinically meaningful and biologically distinct entities, and to identify potential prognostic and predictive biomarkers.

The NAPOLI study is designed to assemble a large international cohort of patients with HR-negative/low and/or HER2-positive ILC, with a special focus on apocrine/LAR features, molecular alterations, imaging presentation, multidisciplinary treatment patterns, response to neoadjuvant therapies, surgical and axillary management, recurrence patterns, and oncologic outcomes. The overarching aim is to generate disease-specific evidence to improve risk stratification, identify clinically relevant prognostic and predictive biomarkers, guide multidisciplinary management (i.e. the use of neoadjuvant chemotherapy) and support future translational and biomarker-driven studies in this rare and underexplored subgroup of BC.

Tipo de estudio

De observación

Inscripción (Estimado)

250

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

      • Padova, Italia
        • Reclutamiento
        • Veneto Institute of Oncology
        • Contacto:
        • Contacto:
        • Sub-Investigador:
          • Francesco Milardi

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

N/A

Método de muestreo

Muestra no probabilística

Población de estudio

Patients diagnosed between January 1, 2010 and December 31, 2025 will be included. Follow-up will be collected until the most recent available clinical update.

Descripción

Inclusion Criteria:

  • Female or male patients aged ≥18 years;
  • Histologically confirmed ILC, confirmed by E-cadherin loss/aberrant expression and/or p120 cytoplasmic relocalization and/or CDH1 alteration;
  • HR-negative (ER <1% and PR <1%) or HR-low (ER and/or PR 1-10%) disease, as defined by ASCO/CAP guidelines, is eligible regardless of HER2 status (assessed according to 2025 ASCO/CAP criteria, with HER2-low and HER2-ultralow status recorded where assessable);
  • HR-positive (ER>10% according to the ASCO/CAP guidelines) ILC is eligible only if HER2 status is positive;
  • Mixed ductal-lobular carcinomas are eligible provided that a clearly identified invasive lobular component is present and predominant (>50% lobular) and HR-negative/low criteria are met;
  • Stage I-III disease at diagnosis; Patients with de novo stage IV disease who underwent surgery of the primary tumor will not be included in the main study cohort but may be captured in a separate exploratory cohort for dedicated analysis;
  • Patients who underwent surgery of the primary tumor at the participating institution, either upfront or after neoadjuvant systemic treatment;
  • Diagnosis occurred between 1 January 2000 and 31 December 2025;
  • Minimum follow-up of 12 months for patients without an event, unless recurrence or death occurred earlier;
  • Local review by a dedicated breast pathologist to confirm the diagnosis and the related molecular features, with particular attention to the confirmation of apocrine morphology.

Exclusion Criteria:

  • Pure IC NST without any lobular invasive component;
  • ER or PR expression >10% in the invasive component, in cases with negative HER2 status;
  • In situ lobular neoplasia (lobular carcinoma in situ) without an invasive component;
  • De novo stage IV disease (such patients, if they underwent surgery of the primary tumor, will be captured in a separate exploratory cohort for a dedicated analysis)
  • Synchronous invasive BC of another dominant histology requiring systemic treatment that precludes attribution of outcomes to HR-negative/low ILC;
  • Prior invasive BC under active systemic treatment at the time of diagnosis, unless clearly documented as unrelated and not expected to confound outcomes;
  • Insufficient data or follow up

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Triple-negative ILC
ER <1%, PR <1% and HER2-negative (IHC 0, 1+, or 2+ with negative ISH). Within this cohort, HER2 expression will be further categorized, where assessable, as HER2 null (IHC 0, no staining), HER2-ultralow (IHC 0+ with faint/incomplete staining in ≤10% of tumor cells) and HER2-low (IHC 1+, or 2+/ISH-negative).
Upfront Conservative or Demolitive Breast Surgery
Adjuvant Breast or Chest Wall Radiotherapy after Breast Surgery
Adjuvant or Neoadjuvant Endocrine Therapy
Adjuvant or Neoadjuvant Chemotherapy
HER2-positive ILC
HER2-positive disease, defined as IHC 3+ or IHC 2+ ISH-positive. Subgroups within this cohort will include HR-negative ILC (ER and PR both <1%) and HR-positive (ER>10%) HER2-positive ILC.
Upfront Conservative or Demolitive Breast Surgery
Adjuvant Breast or Chest Wall Radiotherapy after Breast Surgery
Adjuvant or Neoadjuvant Endocrine Therapy
Adjuvant or Neoadjuvant Chemotherapy
HR-low ILC (cross-cutting category)
ER and/or PR 1-10%, with neither receptor >10%, analyzed separately as a distinct group and also within the HER2-defined groups.
Upfront Conservative or Demolitive Breast Surgery
Adjuvant Breast or Chest Wall Radiotherapy after Breast Surgery
Adjuvant or Neoadjuvant Endocrine Therapy
Adjuvant or Neoadjuvant Chemotherapy
Exploratory Subgroups (cross-cutting category)
Apocrine and/or LAR-featured ILC, and non-classic lobular variants (pleomorphic, histiocytoid and other rare histologic variants).
Upfront Conservative or Demolitive Breast Surgery
Adjuvant Breast or Chest Wall Radiotherapy after Breast Surgery
Adjuvant or Neoadjuvant Endocrine Therapy
Adjuvant or Neoadjuvant Chemotherapy

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Invasive disease-free survival (iDFS)
Periodo de tiempo: Through study completion, an average of 5 years
Time from definitive surgery to first invasive event (ipsilateral invasive, locoregional invasive, or distant recurrence, contralateral invasive BC)
Through study completion, an average of 5 years

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Overall survival (OS)
Periodo de tiempo: Through study completion, an average of 5 years
Through study completion, an average of 5 years
Distant disease-free survival (DDFS)
Periodo de tiempo: Through study completion, an average of 5 years
Through study completion, an average of 5 years
Breast cancer-specific survival (BCSS)
Periodo de tiempo: Through study completion, an average of 5 years
Through study completion, an average of 5 years
Locoregional recurrence-free survival (LRRFS)
Periodo de tiempo: Through study completion, an average of 5 years
Through study completion, an average of 5 years
Recurrence rate and patterns
Periodo de tiempo: Through study completion, an average of 5 years
Local, regional, distant, contralateral, and site-specific distant (including ILC-enriched sites)
Through study completion, an average of 5 years

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Pathologic complete response (pCR) - ypT0/Tis ypN0, with residual cancer burden (RCB) class distribution; in the neoadjuvant cohort, event-free survival (EFS) from treatment initiation where data permit
Periodo de tiempo: Through study completion, an average of 5 years
Through study completion, an average of 5 years
Multidisciplinary treatment patterns and treatment-related outcomes according to therapeutic strategy (upfront surgery versus neoadjuvant treatment), surgical management (including reconstruction/oncoplastic approaches), systemic and radiation therapy
Periodo de tiempo: Through study completion, an average of 5 years
Through study completion, an average of 5 years
Prognostic, predictive and potential therapeutic relevance of clinicopathologic, molecular, and biologic features
Periodo de tiempo: Through study completion, an average of 5 years
Somatic and germline alterations, TME features (stromal TILs, PD-L1 status, immune-related biomarkers), apocrine differentiation, LAR phenotype, HER2 status, HR-negative versus HR-low status, and classic versus pleomorphic/non-classic ILC variants
Through study completion, an average of 5 years
Biomarker-outcome associations with iDFS, pCR and OS
Periodo de tiempo: Through study completion, an average of 5 years
Through study completion, an average of 5 years

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Silla de estudio: Francesco Milardi, MD, Veneto Institute of Oncology IRCCS

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Enlaces Útiles

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de mayo de 2026

Finalización primaria (Estimado)

1 de mayo de 2027

Finalización del estudio (Estimado)

31 de diciembre de 2027

Fechas de registro del estudio

Enviado por primera vez

19 de mayo de 2026

Primero enviado que cumplió con los criterios de control de calidad

23 de mayo de 2026

Publicado por primera vez (Actual)

29 de mayo de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

2 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

30 de agosto de 2026

Última verificación

1 de agosto de 2026

Más información

Términos relacionados con este estudio

Palabras clave

Otros números de identificación del estudio

  • CESC IOV 2023-61

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .